at Zacks.com (Thu, 10:51AM)
SA writer David Zanoni recommends having a look at Celgene (CELG -1.5%), citing its 5 FDA-approved cancer drugs and its extensive pipeline. What Zanoni really likes, though, is Celgene's earnings growth, which is forecast at an average of 25% over the next five years. If that is achieved, "Celgene's stock price of (about) $65 should grow to around $200."
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Thu, 8:59AM)
at Zacks.com (Tue, 4:45PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs